Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Type I DNA Topoisomerases. Found 5 abstracts

Langer CJ. Irinotecan in advanced lung cancer: focus on North American trials. Oncology (Huntington). 2004 Jun;18(7 Suppl 4):17-28.
Hudes G. Boosting bioavailability of topotecan: what do we gain?. J Clin Oncol. 2002 Jul;20(13):2918-9.
Bookman MA. Developmental chemotherapy in advanced ovarian cancer: incorporation of topoisomerase-I inhibitors and perspective of the Gynecologic Oncology Group. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2001 Jan;11 Suppl 1:42-51.
Huang CH, Treat J. New advances in lung cancer chemotherapy: topotecan and the role of topoisomerase I inhibitors. Oncology. 2001 Jan;61 Suppl 1:14-24.
Zhang X, Minale L, Zampella A, Smith CD. Microfilament depletion and circumvention of multiple drug resistance by sphinxolides. Cancer Res. 1997 Sep;57(17):3751-8.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Type I DNA Topoisomerases

Type I DNA Topoisomerases Human Enzyme Inhibitors Female drug therapy antagonists & inhibitors Antineoplastic Agents drug effects Topotecan Antineoplastic Combined Chemotherapy Protocols Oral Administration Non-Small-Cell Lung Carcinoma Multiple Drug Resistance Lung Neoplasms administration & dosage Deoxycytidine pharmacology metabolism Prognosis Survival Analysis Non-US Gov't Support Small Cell Carcinoma mortality Use] Type II DNA Topoisomerases tu [Therapeutic Use] Adjuvant Radiotherapy Antitumor Drug Screening Assays Type I) EC 5-99-1-2 (DNA Topoisomerases ai [Antagonists & Inhibitors] Taxoids 951-77-9 (Deoxycytidine) Isoquinolines diagnosis Carboplatin 0 (Antineoplastic Combined Chemotherapy Protocols) DNA Fragmentation Actins 53643-48-4 (Vindesine) Paclitaxel DNA Adducts 0 (Taxoids) enzymology therapy analogs & derivatives Microfilaments Pyrans Treatment Outcome Neoplasm Proteins drug dt [Drug Therapy] Biological Availability Acridines ultrastructure 33419-42-0 (Etoposide) Intestinal Absorption HL-60 Cells Adenosinetriphosphatase Porifera Randomized Controlled Trials US Gov't Support-PHS EC 1-17-4 (Ribonucleotide Reductases) Male Animal Comparative Study Polymers 103882-84-4 (gemcitabine) tu [Therapeutic Antineoplastic Antimetabolites ATP-Binding Cassette Transporters ad [Administration & Dosage] Neoplasm Drug Resistance Phytogenic Antineoplastic Agents Cultured Tumor Cells 7689-03-4 (Camptothecin) North America Ribonucleotide Reductases Ovarian Neoplasms Liposomes Phytogenic) 0 (Antineoplastic Agents Biological Response Modifiers Camptothecin Cell Cycle Antineoplastic) 0 (Antimetabolites chemistry pharmacokinetics Cytotoxins Cisplatin Smooth Muscle-Vascular aa [Analogs & Derivatives] Breast Neoplasms 0 (Antineoplastic Agents) Etoposide Clinical Trials pathology 15663-27-1 (Cisplatin) Survival Rate Cytochalasin B Carcinoma therapeutic use 100286-90-6 (irinotecan) Vindesine P-Glycoprotein 0 (Enzyme Inhibitors)
Last updated on Monday, July 13, 2020